8-KEarnings & ResultsExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Jul 27, 2017)

Filed July 27, 2017For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) filed an 8-K on July 27, 2017, to announce its financial results for the second quarter of 2017, ending July 26, 2017. The filing primarily consists of furnishing a press release and supplemental information related to these results. Investors should refer to the furnished exhibits (99.1 and 99.2) for the detailed financial performance, operational updates, and forward-looking statements for the second quarter of 2017. This report serves as the official notification of BMY's financial performance during the specified period and provides the primary source for detailed earnings information. While the 8-K itself does not contain the specific financial figures, it directs investors to the press release and supplemental materials for these crucial details. These documents are essential for understanding the company's revenue, earnings per share, product performance, and any significant business developments or strategic outlooks that may impact the company's valuation and future prospects. Investors are encouraged to review these attached materials thoroughly for a comprehensive understanding of BMY's second-quarter performance.

Key Highlights

  • 1BMY filed an 8-K on July 27, 2017, reporting its Q2 2017 financial results.
  • 2The filing primarily serves to furnish a press release (Exhibit 99.1) detailing the Q2 2017 financial and operational performance.
  • 3Supplemental financial information was also provided as Exhibit 99.2, accessible on the company's website.
  • 4Investors are directed to the furnished exhibits for specific Q2 2017 earnings data and business updates.
  • 5The report confirms the event date for the financial results announcement was July 26, 2017.
  • 6No specific financial figures are included directly within the 8-K filing itself, requiring review of the exhibits.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially announce and provide access to Bristol-Myers Squibb's financial results for the second quarter of 2017. It directs investors to the accompanying press release and supplemental information for the detailed financial performance and operational updates.

The actual Q2 2017 financial results are not included directly in the 8-K filing. You need to refer to Exhibit 99.1 (the press release) and Exhibit 99.2 (supplemental information) which are furnished with this 8-K filing and incorporated by reference.

The press release and supplemental information typically contain detailed financial metrics such as revenue, earnings per share (EPS), profit margins, product sales breakdown, and potentially commentary on business performance, strategic initiatives, and forward-looking guidance for the second quarter of 2017.

This 8-K filing is routine for publicly traded companies like Bristol-Myers Squibb, as it is the standard method for announcing quarterly financial results and significant corporate events to the public and the SEC shortly after the period ends.